Factors Influencing Adverse Events Following Immunization (AEFI) of the COVID-19 vaccine: A Case Study in Ubon Ratchathani Province, Thailand

Main Article Content

Teeraporn Sadira Supapaan https://orcid.org/0000-0002-6887-8181
Kittiyaporn Thongthai
Pongdanai Vinitchai https://orcid.org/0009-0009-5863-8983
Wicharut Praken https://orcid.org/0009-0001-6462-2621
Suttasinee Suwannakul
Prasittichai Poonphol https://orcid.org/0000-0002-5215-9449
Sisira Donsamak https://orcid.org/0000-0003-4031-4760
Tuanthon Boonlue https://orcid.org/0000-0001-7930-0054
Nonglek Kunawaradisai
Wannisa DONGTAI Dongtai
Uraiwan Akanit https://orcid.org/0000-0003-4535-0402
Sawaeng Watcharathanakij https://orcid.org/0000-0002-6790-4085
Saksit Sripa https://orcid.org/0000-0002-1528-8006
Patcharee Kanjanawat
Jakkrit Busapan
Chonladda Pitchayajittipong https://orcid.org/0000-0001-6003-7145
Peerawat Jinatongthai https://orcid.org/0000-0002-7954-2480

Keywords

Factors, Adverse Events Following Immunization (AEFI), COVID-19 Vaccine, Thailand

Abstract

Background: The rapid development, approval, and distribution of these vaccines highlight the need to carefully assess their safety. One significant concern is the incidence of Adverse Events Following Immunization (AEFI). There are few reports on the factors influencing AEFI and differences in AEFI among different COVID-19 vaccine brands in Thailand. Exploration of the incidence and factors related to post-vaccination adverse reactions against SARSCoV- 2 in the population attending vaccination centers in Thailand is considered pivotal. Objective: To investigate the incidence and factors associated with adverse events following the administration of the COVID-19 vaccine in the Ubon Ratchathani province. Methods: We analyzed data from individuals who received COVID-19 vaccinations in Ubon Ratchathani province between June 1, 2021, and July 31, 2022. Results: The study examined data from 2,955,978 COVID-19 vaccines administered in Ubon Ratchathani province. Among these, 3.34% experienced an AEFI, further categorized into events occurring within 30 min (0.17%) and after 30 min (3.19%) of vaccination. The occurrences were higher in females compared to males. The age groups exhibited distinct AEFI rates, with children aged 5–17 years and adults aged 18–60 years facing a higher risk. Additionally, individuals with comorbidities are more likely to experience AEFI. The brand of the vaccine and the number of doses administered also influenced AEFI rates. This comprehensive analysis provides valuable insights into AEFI reports, vaccine brands, and associated risk factors, and offers crucial information for vaccine safety monitoring and management. Conclusion: This COVID-19 vaccine adverse events study revealed that higher odds of adverse events were associated with being female, younger, having comorbidities, brand of vaccines, or getting over two doses. These findings provide valuable real-world safety information regarding different COVID-19 vaccines, aiding healthcare professionals and policymakers in effectively monitoring and managing vaccine-related AEFI.

Abstract 187 | PDF Downloads 146

References

1. Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. Febs j. 2020;287(17):3633-50. https://doi.org/10.1111/febs.15375
2. Vannabouathong C, Devji T, Ekhtiari S, Chang Y, Phillips SA, Zhu M, et al. Novel coronavirus COVID-19: current evidence and evolving strategies. J Bone Joint Surg Am. 2020;102(9):734-44. https://doi.org/10.2106/jbjs.20.00396
3. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Napoli R. (2023). Features, evaluation, and treatment of Coronavirus (COVID-19)
https://www.ncbi.nlm.nih.gov/books/NBK554776/. Accessed 2 Jan, 2023.
4. Okuyama R. mRNA and adenoviral vector vaccine platforms utilized in COVID-19 vaccines: technologies, ecosystem, and futuredirections. Vaccines (Basel). 2023;11(12):1737. https://doi.org/10.3390/vaccines11121737
5. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023-34. https://doi.org/10.1016/s0140-6736(21)00306-8
6. Kashte S, Gulbake A, El-Amin Iii SF, Gupta A. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. 2021;34(3):711-33. https://doi.org/10.1007/s13577-021-00512-4
7. Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85-100. https://doi.org/10.1016/j.biochi.2020.09.018
8. Sebastian J, Gurumurthy P, Ravi MD, Ramesh M. Active surveillance of adverse events following immunization (AEFI): a prospective 3-year vaccine safety study. Ther Adv Vaccines Immunother. 2019;7:2515135519889000. https://doi.org/10.1177/2515135519889000
9. World Health Organization (WHO). (2012). Adverse events following immunization. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/aefi/aefi. Accessed 2 Jan, 2023.
10. Bhandari B, Rayamajhi G, Lamichhane P, Shenoy AK. Adverse events following Immunization with COVID-19 Vaccines: a narrative review. Biomed Res Int. 2022;2022:2911333. https://doi.org/10.1155/2022/2911333
11. Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, et al. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021;19(1):173. https://doi.org/10.1186/s12916-021-02059-5
12. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2
trial. Lancet. 2020;396(10249):479-88. https://doi.org/10.1016/s0140-6736(20)31605-6
13. Tran VN, Nguyen HA, Le TTA, Truong TT, Nguyen PT, Nguyen TTH. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021. Vaccine. 2021;39(44):6485-91. https://doi.org/10.1016/j.vaccine.
2021.09.060
14. Rayamajhi S, Rafi MA, Tripathi N, Dongol AS, Pandey M, Rayamajhi S, et al. Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal. PLoS One.
2022;17(8):e0272729. https://doi.org/10.1371/journal.pone.0272729
15. Kaur S, Singh A, Saini S, Rohilla L, Kaur J, Chandi A, et al. Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (recombinant) among the vaccinated healthcare professionals: a cross-sectional survey. Indian J Med Res. 2022;155(1):123-8.
https://doi.org/10.4103/ijmr.ijmr_1221_21
16. WHO COVID-19 dashboard. (2023). COVID-19 vaccination, World data. https://data.who.int/dashboards/covid19/vaccines? n=c. Accessed 2 Jan, 2024.
17. The Centre for COVID-19 Situation Administration. (2020). Order of the Prime Minister No. 6/2563 Re : Arrangement of the Structure of the Centre for COVID-19 Situation Administration (CCSA). https://www.mfa.go.th/en/content/1177x?page=5f-
22514b78568958aa0d5b85&menu=5f2253d49864ad7325088af4. Accessed 2 Jan, 2023.
18. Tangcharoensathien V. (2020). Decision making for social and movement measures in the context of COVID-19. https://cdn. who.int/media/docs/default-source/health-governance-and-financing/thailand.pdf?sfvrsn=581a7461_9. Accessed 2 Jan,
2023.
19. Mahasing C, Doungngern P, Jaipong R, Nonmuti P, Chimmanee J, Wongsawat J, et al. Myocarditis and pericarditis following COVID-19 vaccination in Thailand. Vaccines (Basel). 2023;11(4):749. https://doi.org/10.3390/vaccines11040749
20. Division of Epidemiology Department of Disease Control Thailand. (2021). Manual for adverse event following COVID-19 iImmunization surveillance. https://apps-doe.moph.go.th/boe/software/file/Guideline_AEFI_COVID19vaccine_DOE_17062021.
pdf. Accessed 2 Jan, 2024.
21. Maiman P. Adverse events following immunization: AEFI. J Health Consumer Protection. 2022;2(1):83-99.
22. Department of Disease control Ministry of Public Health. (2023). Adverse events following immunization of COVID-19 vaccine in Thailand (updated 25 Aug 2023). https://ddc.moph.go.th/uploads/ckeditor2//files/AEFI%20Situation_COVID-19%20
Vaccine_25082023_web.pdf. Accessed 2 Jan, 2024.
23. Choppradit C, Likittientong T, Sonthong V. Adverse events following immunization (AEFIs) of COVID-19 vaccine in Samutsakhon Hospital. Hua Hin Med J. 2022;2(3):1-19.
24. Basavaraja CK, Sebastian J, Ravi MD, John SB. Adverse events following COVID-19 vaccination: first 90 days of experience from
a tertiary care teaching hospital in South India. Ther Adv Vaccines Immunother. 2021;9:25151355211055833. https://doi.org/10.1177/25151355211055833
25. Shukla V, Sachan B, Jauhari S, Bhardwaj S, Pathak A, Kandpal SD. Adverse events following COVID-19 immunisation (AEFI) at a COVID-19 vaccination centre: an observational analytical study. J Family Med Prim Care. 2023;12(3):460-5. https://doi.
org/10.4103/jfmpc.jfmpc_1434_22
26. Parida SP, Sahu DP, Singh AK, Alekhya G, Subba SH, Mishra A, et al. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. J Med Virol. 2022;94(6):2453-9. https://doi.org/10.1002/jmv.27655
27. Chakraborty A, Reval N, Kamath L. Adverse events following COVID-19 vaccination in selected apartments in Bangalore, India. Cureus. 2022;14(2):e21809. https://doi.org/10.7759/cureus.21809
28. Sunil Kumar DR, Srividya J, Apoorva EP, Vidya R. Covid-19 vaccination coverage and break through infections in urban slums of Bengaluru, India: a cross sectional study. medRxiv. 2021:2021.2011.2021.21262716.
29. Sultana A, Shahriar S, Tahsin MR, Mim SR, Fatema KR, Saha A, et al. A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines (Basel). 2021;9(10):1090.
https://doi.org/10.3390/vaccines9101090
30. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021;4(12):e2140364. https://doi.org/10.1001/jamanetworkopen.2021.40364
31. Silwal K, Kodali PB, Sharma H, Tewani GR, Nair PMK. Impact of COVID-19 vaccines on the health status of young female adults from India: A cross-sectional study. J Family Med Prim Care. 2023;12(2):338-51. https://doi.org/10.4103/jfmpc.jfmpc_1574_22
32. Vassallo A, Shajahan S, Harris K, Hallam L, Hockham C, Womersley K, et al. Sex and gender in COVID-19 vaccine research: substantial evidence gaps remain. Front Glob Womens Health. 2021;2:761511. https://doi.org/10.3389/fgwh.2021.761511
33. Heidari S, Goodman T. Critical sex and gender considerations for equitable research, development and delivery of COVID-19 vaccines: background paper. 2021.
34. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2019;41(2):239-49. https://doi.org/10.1007/s00281-018-0726-5
35. Al-Qazaz HK, Al-Obaidy LM, Attash HM. COVID-19 vaccination, do women suffer from more side effects than men? a retrospective cross-sectional study. Pharm Pract (Granada). 2022;20(2):2678. https://doi.org/10.18549/pharmpract.2022.2.2678
36. Chang WH. A review of vaccine effects on women in light of the COVID-19 pandemic. Taiwan J Obstet Gynecol. 2020;59(6):812- 20. https://doi.org/10.1016/j.tjog.2020.09.006
37. Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9-15. https://doi.org/10.1093/trstmh/tru167
38. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38. https://doi.org/10.1038/nri.2016.90
39. Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines (Basel). 2022;10(2):233. https://doi.org/10.3390/vaccines10020233
40. Alemayehu A, Yusuf M, Demissie A, Abdullahi Y. Determinants of COVID-19 vaccine uptake and barriers to being vaccinated among first-round eligibles for COVID-19 vaccination in Eastern Ethiopia: A community based cross-sectional study. SAGE Open
Med. 2022;10:20503121221077585. https://doi.org/10.1177/20503121221077585
41. Kim A-S, Kim S-M, Song J-E, Hwang S, Nam E, Kwon KT. Adverse reactions after BNT162b2 messenger RNA vaccination for Coronavirus Disease 2019 in healthcare workers compared with influenza vaccination. Vaccines. 2023;11(2):363. https://doi.org/10.3390/vaccines11020363
42. Ouaddouh C, Duijster JW, Lieber T, van Hunsel F. The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands. Expert Opin Drug Saf. 2023:1-9.
https://doi.org/10.1080/14740338.2023.2267971
43. Rahmat H, Leelavathi M, Wan Ismail WF. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination. Med J Malaysia. 2022;77(6):637-42.
44. Serrano-Arias B, Ferrara F, Zavaleta E, Zovi A, Ortiz-Barboza A, Pasquinucci R, et al. Adverse events following mRNA COVID-19 vaccine in 2021 and 2022: a retrospective analysis in Costa Rica and Italy. Cureus. 2023;15(10):e47834. https://doi.org/10.7759/cureus.47834
45. van der Boor SC, Schmitz-de Vries ETJ, Smits D, Scholl JHG, Rolfes L, van Hunsel F. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands. Vaccine. 2023;41(29):4319-26. https://doi.org/10.1016/j.
vaccine.2023.05.053
46. Oosterhuis I, Scholl J, van Puijenbroek E, Kant A, van Hunsel F. Optimizing safety surveillance for COVID-19 vaccines at the National Pharmacovigilance Centre Lareb: one year of COVID-19 vaccine experience. Drug Saf. 2023;46(1):65-75. https://doi.org/10.1007/s40264-022-01253-5
47. Marfoh K, Samba A, Okyere E, Acheampong F, Owusu E, Darko DNA, et al. Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana. BMJ Open. 2023;13(6):e061643.
https://doi.org/10.1136/bmjopen-2022-061643
48. Yan MM, Zhao H, Li ZR, Chow JW, Zhang Q, Qi YP, et al. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS. Front Pharmacol. 2022;13:921760. https://doi.org/10.3389/fphar.2022.921760
49. Tan TL, Salleh SA, Che Man Z, Tan MHP, Kader R, Jarmin R. BNT162b2 COVID-19 vaccination and its effect on blood pressure. Medicina (Kaunas). 2022;58(12):1789. https://doi.org/10.3390/medicina58121789
50. Hata Y, Kimura Y, Muratani H, Fukiyama K, Kawano Y, Ashida T, et al. Office blood pressure variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res. 2000;23(6):553-60. https://doi.org/10.1291/hypres.23.553
51. Ong TZ, Raymond AA. Risk factors for stroke and predictors of one-month mortality. Singapore Med J. 2002;43(10):517-21.
52. Oteh M, Azarisman SM, Azreen SA, Jamaluddin AR, Aszrin A, Ting CK, et al. Institutional hypertension control in Malaysia: a multicenter study focusing on gender and cardiovascular risk factor profile difference. Hypertens Res. 2011;34(3):19-324.
https://doi.org/10.1038/hr.2010.239
53. McCloskey LW, Psaty BM, Koepsell TD, Aagaard GN. Level of blood pressure and risk of myocardial infarction among treated hypertensive patients. Arch Intern Med. 1992;152(3):513-20.
54. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1(8121):861-5. https://doi.org/10.1016/s0140-6736(79)91274-1
55. Fletcher AE, Beevers DG, Bulpitt CJ, Butler A, Coles EC, Hunt D, et al. The relationship between a low treated blood pressure and IHD mortality: a report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1988;2(1):11-5.
56. Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med. 2022;386(20):1910-21. https://doi.org/10.1056/nejmoa2200674
57. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and
a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infect Dis. 2022;22(8):1131-41. https://doi.org/10.1016/s1473-3099(22)00271-7
58. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre,
randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258-76. https://doi.org/10.1016/s0140-6736(21)02717-3
59. Christou-Ergos M, Wiley KE, Leask J. Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others. Vaccine. 2023;41(1):246-50. https://doi.org/10.1016/j.vaccine.2022.11.034
60. Zeitoun A, Hallit S, Chehade S, Ibrahim A, Helali M, Allam C, et al. A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study. J Pharm Policy Pract. 2023;16(1):24. https://doi.org/10.1186/s40545-023-00528-1
61. Luo C, Du J, Cuker A, Lautenbach E, Asch DA, Poland GA, et al. Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety. Sci Rep. 2022;12(1):10946. https://doi.org/10.1038/s41598-022-13809-7
62. Malande OO, Munube D, Afaayo RN, Chemweno C, Nzoka M, Kipsang J, et al. Adverse events following immunization reporting and impact on immunization services in informal settlements in Nairobi, Kenya: a prospective mixed-methods study. Pan Afr
Med J. 2021;40:81. https://doi.org/10.11604/pamj.2021.40.81.25910
63. Naranjo D, Kimball E, Nelson J, Samore M, Alder SC, Stroupe K, et al. Differences in perceptions and acceptance of COVID-19 vaccination between vaccine hesitant and non-hesitant persons. PLoS One. 2023;18(9):e0290540. https://doi.org/10.1371/journal.pone.0290540
64. Rudolph A, Mitchell J, Barrett J, Sköld H, Taavola H, Erlanson N, et al. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge. Ther Adv Drug Saf. 2022;13:20420986221118972. https://doi.org/10.1177/20420986221118972
65. de Germay S, Singier A, Salvo F, Pariente A. Impact of Covid-19 vaccination on spontaneous pharmacovigilance reporting in
France. Drug Saf. 2023;46(12):1381-9. https://doi.org/10.1007/s40264-023-01359-4
66. Sisay MM, Montesinos-Guevara C, Osman AK, Saraswati PW, Tilahun B, Ayele TA, et al. COVID-19 vaccine safety monitoring studies in low- and middle-income countries (LMICs)- a systematic review of study designs and methods. Vaccines.
2023;11(6):1035. https://doi.org/10.3390/vaccines11061035
67. Aborigo RA, Welaga P, Oduro A, Shaum A, Opare J, Dodoo A, et al. Optimising reporting of adverse events following immunisationby healthcare workers in Ghana: a qualitative study in four regions. PLoS One. 2022;17(12):e0277197. https://doi.org/10.1371/journal.pone.0277197
68. Nehme A, Barakat M, Malaeb D, Obeid S, Hallit S, Haddad G. Association between COVID-19 symptoms, COVID-19 vaccine, and somatization among a sample of the Lebanese adults. Pharm Pract (Granada). 2023;21(1):2763. https://doi.org/10.18549/pharmpract.2023.1.2763
69. Kant A, Jansen J, van Balveren L, van Hunsel F. Description of frequencies of reported adverse events following immunization among four different COVID-19 vaccine brands. Drug Saf. 2022;45(4):319-31. https://doi.org/10.1007/s40264-022-01151-w
70. Cokro F, Sharon, Hadiyanto. Supporting and inhibiting factors of accepting COVID-19 booster vaccination in the elderly in north Jakarta, Indonesia. Pharm Pract (Granada). 2022;20(4):2748. https://doi.org/10.18549/pharmpract.2022.4.2748
71. Hudson A, Montelpare WJ. Predictors of vaccine hesitancy: implications for COVID-19 public health messaging. Int J Environ Res Public Health. 2021;18(15):8054. https://doi.org/10.3390/ijerph18158054
72. Harrison EA, Wu JW. Vaccine confidence in the time of COVID-19. Eur J Epidemiol. 2020;35(4):325-30. https://doi.org/10.1007/s10654-020-00634-3
73. Luyten J, Bruyneel L, van Hoek AJ. Assessing vaccine hesitancy in the UK population using a generalized vaccine hesitancy survey instrument. Vaccine. 2019;37(18):2494-501. https://doi.org/10.1016/j.vaccine.2019.03.041
74. Awijen H, Ben Zaied Y, Nguyen DK. Covid-19 vaccination, fear and anxiety: Evidence from Google search trends. Soc Sci Med. 2022;297:114820. https://doi.org/10.1016/j.socscimed.2022.114820
75. Hawila B, Malaeb D, Hallit S, Obeid S. Association between Covid-19 vaccination, fear of COVID-19 and female sexual satisfaction among a sample of Lebanese women: A pilot study. Pharm Pract (Granada). 2023;21(2):2776. https://doi.org/10.18549/PharmPract.2023.2.2776

Most read articles by the same author(s)